This article was originally published by Targeted Oncology. C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of chimeric antigen receptor (CAR) T cells and CAR natural killer (NK) cells in the multiple myeloma setting. As with every therapy, there are pros and cons...Continue Reading

Hamilton Myeloma Semimar, Saturday 5 September Come along to our Hamilton Myeloma Patient Seminar, hosted by MyelomaNew Zealand and Leukaemia & Blood Cancer New Zealand. During the morning, we will hear from Dr Henry Chan (Waitemata DHB) and Dr Hugh Goodman (Waikato DHB) who will discuss some of the changes to come in 2020 for...Continue Reading